Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status

Gülin Öz, Diane Hutter, Ivan Tkáč, H. Brent Clark, Myron D. Gross, Hong Jiang, Lynn E. Eberly, Khalaf O. Bushara, Christopher M. Gomez

Research output: Contribution to journalArticlepeer-review

87 Scopus citations


Robust biomarkers of neurodegeneration are critical for testing of neuroprotective therapies. The clinical applicability of such biomarkers requires sufficient sensitivity to detect disease in individuals. Here we tested the sensitivity of high field (4 tesla) proton magnetic resonance spectroscopy (1H MRS) to neurochemical alterations in the cerebellum and brainstem in spinocerebellar ataxia type 1 (SCA1). We measured neurochemical profiles that consisted of 10 to 15 metabolite concentrations in the vermis, cerebellar hemispheres and pons of patients with SCA1 (N = 9) and healthy controls (N = 15). Total NAA (N-acetylaspartate + N-acetylaspartylglutamate, tNAA) and glutamate were lower and glutamine, myo-inositol and total creatine (creatine + phosphocreatine, tCr) were higher in patients relative to controls, consistent with neuronal dysfunction/loss, gliotic activity, and alterations in glutamate - glutamine cycling and energy metabolism. Changes in tNAA, tCr, myo-inositol, and glutamate levels were discernible in individual spectra and the tNAA/myo-inositol ratio in the cerebellar hemipheres and pons differentiated the patients from controls with 100% specificity and sensitivity. In addition, tNAA, myo-inositol, and glutamate levels in the cerebellar hemispheres and the tNAA and myo-inositol levels in the pons correlated with ataxia scores (Scale for the Assessment and Rating of Ataxia, SARA). Two other biomarkers measured in the cerebrospinal fluid (CSF) of a subset of the volunteers (F 2-isoprostanes as a marker of oxidative stress and glial fibrillary acidic protein (GFAP) as a marker of gliosis) were not different between patients and controls. These data demonstrate that 1H MRS biomarkers can be utilized to noninvasively assess neuronal and glial status in individual ataxia patients.

Original languageEnglish (US)
Pages (from-to)1253-1261
Number of pages9
JournalMovement Disorders
Issue number9
StatePublished - Jul 15 2010


  • Ataxia
  • Cerebellum
  • MRS
  • Neurochemical profile
  • SCA1


Dive into the research topics of 'Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status'. Together they form a unique fingerprint.

Cite this